Aevi Genomic Medicine, Inc. reported unaudited consolidated earnings results for the second quarter and six months ended June 30, 2017. For the quarter, the company reported operating loss of USD 8,036,000 against USD 11,686,000 a year ago. Loss before taxes on income was USD 8,033,000 against USD 11,704,000 a year ago. Net loss was USD 8,033,000 or USD 0.22 per basic and diluted share against USD 11,707,000 or USD 0.35 per basic and diluted share a year ago. For the six months, the company reported operating loss of USD 18,971,000 against USD 22,828,000 a year ago. Loss before taxes on income was USD 18,950,000 against USD 22,848,000 a year ago. Net loss was USD 18,950,000 or USD 0.51 per basic and diluted share against USD 22,851,000 or USD 0.69 per basic and diluted share a year ago.